Adam Feuerstein✡️

@adamfeuerstein.bsky.social

Reporter at STAT. The Harry Kane of biotech. Dog ❤️er. Polk Award winner. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech is in a dark place. The market offers one beatdown after another. Sentiment is lousy and the bad mood is relentless, to the point where people are seriously wondering if a sector turnaround is ever possible. Sorry, but it's just depressing out there... www.statnews.com/2025/02/13/b...

Biotech is in a dark place

Biotech and drug stocks, collectively, are down an average of 16% over the past three months. The closely watched XBI index is down 19% in the same time period.

statnews.com

As outcry builds over Trump cuts to NIH payments, drugmakers are MIA On last night's earnings call, $VRTX CEO Reshma Kewalramani said nothing about the NIH, yet Vertex owes some of that $11B in cystic fibrosis drug sales to foundational biomedical research funded by NIH....

Austin Leclaire was a remarkable young man with Duchenne who raised awareness about his devastating disease, and as a patient advocate, played a pivotal role in spurring the development of the first medicines to treat it. Austin died on Feb. 1. He was 26. www.statnews.com/2025/02/06/a...

Remembering a remarkable Duchenne champion

Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines to treat Duchenne muscular dystrophy.

statnews.com

In this week's Biotech Scorecard newsletter: MASH drugs have reached a meaningful tipping point for patients and investors. $MDGL already topping $400 million in annualized sales. $AKRO reversing cirrhosis in F4 patients + $ETNB following ...